SCHEMBL326214

SCHEMBL326214

OB(O)c1cc(OC(F)(F)F)ccc1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 5/20 0.42
WDR5 P61964 1/20 0.40
ABL1 P00519 1/20 0.37
LMNA P02545 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
MAPT P10636 2/20 0.37
EPHX2 P34913 1/20 0.37
P2RX1 P51575 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KIF11 P52732 1/20 0.37
FFAR4 Q5NUL3 1/20 0.36
AURKA O14965 1/20 0.36
TPX2 Q9ULW0 1/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
PIM1 P11309 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954904 1.00 GPR3 (0.42) GPR3WDR5ABL1LMNANR1H2
SCHEMBL28961819 0.87 GPR3 (0.43) GPR3WDR5ABL1MAPTEPHX2
SCHEMBL257822 0.81 GPR3 (0.42) GPR3ABL1MAPTEPHX2L3MBTL1
SCHEMBL29957379 0.81 GPR3 (0.42) GPR3ABL1LMNAMAPTEPHX2
SCHEMBL3993839 0.80 FFAR4 (0.41) GPR3ABL1FFAR4
SCHEMBL29554405 0.80 FFAR4 (0.41) GPR3ABL1FFAR4
SCHEMBL320667 0.79 TUBB4A (0.46) GPR3ABL1FFAR4
SCHEMBL29956393 0.79 TUBB4A (0.46) GPR3ABL1FFAR4
SCHEMBL24445841 0.78 GPR3 (0.48) GPR3WDR5LMNAMAPTEPHX2
SCHEMBL769093 0.78 GPR3 (0.42) GPR3ABL1MAPTEPHX2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109667-A1 Chemical Compounds SCN1A, SCN7A, SCN1B GPR3 1541/4885WDR5 4198/4885ABL1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.